Technical Analysis for PRVB - Provention Bio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
3.36 | 0.30% | 0.01 |
PRVB closed up 0.3 percent on Wednesday, April 24, 2019, on 1.66 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| See historical PRVB trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bearish? | Reversal | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.30% | |
| Wide Bands | Range Expansion | 0.30% | |
| Above Upper BB | Strength | 0.30% | |
| Overbought Stochastic | Strength | 0.30% | |
| Upper Bollinger Band Touch | Strength | 0.30% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-19
- Sector: Healthcare
- Industry: Biotechnology
Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.
Medicine Biopharmaceutical Medical Specialties Immunology Disease Diabetes Autoimmune Diseases Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Viral Diseases Colitis Lupus Immune Mediated Diseases
Medicine Biopharmaceutical Medical Specialties Immunology Disease Diabetes Autoimmune Diseases Ulcerative Colitis Abdominal Pain Diarrhea Crohn's Disease Viral Diseases Colitis Lupus Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more PRVB news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 8.0 |
| 52 Week Low | 1.52 |
| Average Volume | 42,993 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 2.5083 |
| 20-Day Moving Average | 2.707 |
| 10-Day Moving Average | 3.013 |
| Average True Range | 0.2194 |
| ADX | 43.29 |
| +DI | 33.5483 |
| -DI | 6.5651 |
| Chandelier Exit (Long, 3 ATRs ) | 2.7918 |
| Chandelier Exit (Short, 3 ATRs ) | 2.8582 |
| Upper Bollinger Band | 3.4322 |
| Lower Bollinger Band | 1.9818 |
| Percent B (%b) | 0.95 |
| BandWidth | 53.579608 |
| MACD Line | 0.2331 |
| MACD Signal Line | 0.1571 |
| MACD Histogram | 0.076 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.66 | ||||
| Resistance 3 (R3) | 3.66 | 3.55 | 3.61 | ||
| Resistance 2 (R2) | 3.55 | 3.48 | 3.56 | 3.59 | |
| Resistance 1 (R1) | 3.46 | 3.43 | 3.51 | 3.46 | 3.58 |
| Pivot Point | 3.35 | 3.35 | 3.38 | 3.36 | 3.35 |
| Support 1 (S1) | 3.26 | 3.28 | 3.31 | 3.26 | 3.14 |
| Support 2 (S2) | 3.15 | 3.23 | 3.16 | 3.13 | |
| Support 3 (S3) | 3.06 | 3.15 | 3.11 | ||
| Support 4 (S4) | 3.06 |
